Haohai Biological Technology's shareholder reduction plan draws attention, causing short-term pressure on the stock price

Economic Observer Network Hao Hai Biotechnology’s recent most关注事件 is the shareholder reduction plan. On February 12, 2026, the company announced that shareholder Lou Guoliang, due to personal funding needs, plans to reduce no more than 1 million shares within three months after the announcement through centralized bidding and block trades, accounting for no more than 0.4337% of the company’s total share capital. This reduction plan may exert short-term pressure on market sentiment but aligns with the shareholder’s previous listing commitments.

Recent Stock Performance

Regarding stock performance, Hao Hai Shengke A-shares (688366.SH) have recently underperformed. As of the close on February 13, 2026, the stock price was 45.91 yuan, down 1.21% for the day, with a total decline of 2.28% over the past five days; meanwhile, Hong Kong-listed Hao Hai Biotechnology (06826.HK) closed at HKD 26.72, up 2.06% for the day, but with a five-day fluctuation of 4.55%. Fund flow data shows that on February 13, the net outflow of main funds in A-shares was about 1 million yuan, indicating short-term funding pressure. Technically, the A-share price has broken below the 5-day moving average (46.22 yuan), and the MACD indicator shows a death cross signal; the Hong Kong stock is near the middle band of the Bollinger Bands (HKD 26.034), with the J line of the KDJ indicator rising to 78.96, indicating short-term overbought conditions.

Financial Report Analysis

The company’s performance declined in the third quarter of 2025. According to the third-quarter report, quarterly revenue decreased by 11.29% year-on-year to 595 million yuan, and net profit attributable to shareholders decreased by 11.39% year-on-year to 93.58 million yuan; cumulative revenue for the first three quarters declined by 8.47%, and net profit decreased by 10.63%. Gross profit margin remained at 70.39%, but non-recurring net profit dropped sharply by 44.54%, mainly due to increased sales expenses and market environment impacts.

Institutional Views

Institutions maintain a focus on Hao Hai Biotechnology’s long-term fundamentals. Recent data shows that in February 2026, two institutions issued opinions on the Hong Kong stock, both rated as buy or overweight, with a target price of HKD 56.65, indicating potential upside from the current price. Institutions generally focus on the company’s expansion into medical devices and progress in high-end product lines, but the short-term reduction event may suppress valuation recovery.

The above content is compiled from public information and does not constitute investment advice.

Massive information, precise interpretation, all on Sina Finance APP

【Source: Economic Observer Network】